Khiron Life Sciences operates like a pharmaceutical company, commercializing medical cannabis products, operating trauma treatment facilities and developing pharma-grade beauty products throughout Latin America. Khiron’s model focuses on the patient, fulfilling their needs and understanding their expectations. Khiron prides itself on the development of a safe, consistent and high-quality product which enhances wellbeing for body and mind.
Highlights of their most recent developments are:
Last updated: September, 2019
We think Khiron knows where the puck is going. At a time when its competition is focusing on Europe, the company is targeting the budding Latin American market.
As its President, Chris Naprawa, said: “Do I want to be the 125th LP competing for exports into Germany? Or do I want to be the dominant player in a 620-million-person market?” Having spent years in Colombia, the company knows the landscape. Khiron offers cannabis-infused cosmeceuticals in a region where beauty products are in extremely high-demand. Inkwood Research found the Latin American beauty product market was worth $60 billion in 2017.
The company has already established itself in Mexico, Colombia, Chile and Peru. With access to nearly 68 million potential patients already, Khiron has the potential to dominate the emerging Latin American cannabis sphere.
Alvaro Torres, CEO
Wendy Kaufman, CFO
Chris Naprawa, President